Reviewing Big Cypress Acquisition (OTCMKTS:BCYP) & Kymera Therapeutics (NASDAQ:KYMR)

Big Cypress Acquisition (OTCMKTS:BCYP) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Profitability

This table compares Big Cypress Acquisition and Kymera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Big Cypress Acquisition	N/A	N/A	N/A
Kymera Therapeutics	-191.26%	-24.96%	-20.27%

Insider and Institutional Ownership

60.2% of Big Cypress Acquisition shares are owned by institutional investors. 15.8% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Big Cypress Acquisition and Kymera Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A
Kymera Therapeutics	$47.07 million	44.89	-$146.96 million	($2.97)	-10.96

Big Cypress Acquisition has higher earnings, but lower revenue than Kymera Therapeutics.

Analyst Recommendations

This is a summary of current ratings and price targets for Big Cypress Acquisition and Kymera Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Big Cypress Acquisition	0	0	0	0	0.00
Kymera Therapeutics	0	3	11	1	2.87

Kymera Therapeutics has a consensus target price of $56.36, indicating a potential upside of 73.19%. Given Kymera Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Big Cypress Acquisition.

Summary

Kymera Therapeutics beats Big Cypress Acquisition on 6 of the 11 factors compared between the two stocks.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.